DALY II Japan/MB-CART2019.1 for DLBCL

This trial is testing a CAR-T cell therapy called MB-CART2019.1 — a treatment using your own genetically engineered immune cells to attack cancer — in people with diffuse large B-cell lymphoma (DLBCL) and related aggressive lymphomas that have come back or stopped responding to multiple prior treatments. **You may be eligible if...** - You have a confirmed diagnosis of DLBCL or a related aggressive B-cell lymphoma subtype - Your lymphoma has relapsed or is no longer responding after at least 2 lines of chemotherapy including rituximab and an anthracycline drug - You have either already had and failed a stem cell transplant, or are not eligible for one - You have at least one measurable lesion on imaging **You may NOT be eligible if...** - You have not yet tried at least 2 prior treatment regimens - You have active brain involvement from lymphoma - Your organ function is significantly impaired - You have an active serious infection or another active cancer Talk to your doctor to see if this trial is right for you.